LDS/Medical Tests/Coagulation Factor II Inhibitor Assay, Plasma

Coagulation Factor II Inhibitor Assay, Plasma

Prothrombin (factor II), encoded by the F2 gene, is a vitamin K–dependent serine protease synthesized by the liver and plays a central role in coagulation through its conversion to thrombin. Thrombin generation is essential for fibrin formation, platelet activation, and amplification of the coagulation cascade. In rare cases, individuals develop acquired inhibitors to prothrombin, most commonly immunoglobulin G antibodies, which neutralize factor II activity and result in impaired thrombin generation.

Factor II inhibitors are uncommon but clinically significant and may be associated with autoimmune disease, infections, malignancy, exposure to certain medications, or repeated transfusions of plasma-derived products. In some patients, inhibitors occur in association with lupus anticoagulant–hypoprothrombinemia syndrome, in which bleeding may occur despite the presence of lupus anticoagulant. Clinical presentation ranges from mild mucocutaneous bleeding to severe spontaneous hemorrhage.

Laboratory findings typically include a prolonged prothrombin time (PT) with markedly reduced factor II activity that does not correct on mixing studies, suggesting the presence of an inhibitor rather than a simple deficiency. The Factor II Inhibitor Assay is used to detect and confirm inhibitor-mediated reduction of prothrombin activity and to distinguish acquired inhibitors from congenital or acquired factor II deficiency due to decreased synthesis or consumption.

  • Used in the evaluation of unexplained bleeding with reduced factor II activity
  • To distinguish factor II deficiency from inhibitor-mediated loss of activity
  • Useful in the assessment of autoimmune or antibody-mediated coagulation disorders, including lupus anticoagulant–hypoprothrombinemia syndrome
  • Aids in the investigation of prolonged PT that fails to correct with mixing studies
The presence of a factor II inhibitor is suggested by reduced factor II activity with incomplete or absent correction following mixing with normal plasma. Results should be interpreted in conjunction with factor II activity levels, PT/INR, aPTT, mixing studies, lupus anticoagulant testing, and the patient’s clinical history. Detection of an inhibitor supports an acquired immune-mediated etiology rather than congenital deficiency or reduced synthesis due to liver disease or vitamin K deficiency.

Adults: 75-145%

Newborn infants or healthy premature infants may have decreased levels as low as > or =25%.

Usually this might persist for 2-3 months and before becomes normal.

Clot-based inhibitor assay using patient plasma mixed with normal pooled plasma, with measurement of residual factor II activity utilizing a prothrombin time–based assay and factor II–deficient substrate.

Platelet-poor plasma, 5 mL (patients should ideally not be receiving warfarin, heparin, or direct oral anticoagulants at the time of collection if clinically feasible), sodium citrate (light-blue top vial).

Stability

  • Ambient: 4 hrs.
  • Refrigerated: 24 hrs.
  • Frozen: 14 days.
Factor II activity assay, PT/INR, aPTT, mixing studies, lupus anticoagulant testing, and additional coagulation factor assays as clinically indicated.
1- 3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login